What was UnicoCell Biomed Co., Ltd.’s price range in the past 12 months?
UnicoCell Biomed Co., Ltd. lowest stock price was TWD 63.50 and its highest was TWD 93.20 in the past 12 months.
What is UnicoCell Biomed Co., Ltd.’s market cap?
UnicoCell Biomed Co., Ltd.’s market cap is TWD 4.10B.
When is UnicoCell Biomed Co., Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were UnicoCell Biomed Co., Ltd.’s earnings last quarter?
UnicoCell Biomed Co., Ltd. released its earnings results on Aug 07, 2026. The company reported -TWD 0.393 earnings per share for the quarter.
Is UnicoCell Biomed Co., Ltd. overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does UnicoCell Biomed Co., Ltd. pay dividends?
UnicoCell Biomed Co., Ltd. does not currently pay dividends.
What is UnicoCell Biomed Co., Ltd.’s EPS estimate?
UnicoCell Biomed Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does UnicoCell Biomed Co., Ltd. have?
UnicoCell Biomed Co., Ltd. has 63,637,000 shares outstanding.
What happened to UnicoCell Biomed Co., Ltd.’s price movement after its last earnings report?
UnicoCell Biomed Co., Ltd. reported an EPS of -TWD 0.393 in its last earnings report. Following the earnings report the stock price went down -1.527%.
Which hedge fund is a major shareholder of UnicoCell Biomed Co., Ltd.?
Currently, no hedge funds are holding shares in TW:6794
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
UnicoCell Biomed Co., Ltd.
UnicoCell Biomed Co., Ltd., a Taiwanese enterprise, specializes in the research, development, and application of stem cell-based pharmaceuticals, advanced cell therapy techniques, and regenerative medical solutions. Their flagship product, ELIXCYTE, is presently undergoing Phase 2 clinical trials, targeting both osteoarthritis and chronic kidney disease. Beyond therapeutics, the company also offers UnicoVial, a specialized cryopreservation and drug containment system designed for cell therapy products, and provides a range of related testing services.
Sector
General
Industry
Biotechnology
CEO
Yi-Pei Hung
Employees
27
Website
www.unicocell.com
Address
No. 13-20, Minquan East Road, Taipei, TP, 11494, TW